Archived article
Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.
Tissue Regenix Group PLC - Leeds, England-based regenerative medical devices company - In response to press reports, say that it is conducting a review of strategic options, which may include soliciting offers for Tissue Regenix. Accordingly, the firm has contacted a limited number of potential counterparties to assess whether they could put forward a proposal ‘that would deliver greater value to Tissue Regenix’s shareholders than pursuing a standalone independent strategy’. Says it has not received any indicative non-binding proposals to date, and says there can be no certainty any offer will be made.
Current stock price: 61.67 pence
12-month change: up 10%
Copyright 2024 Alliance News Ltd. All Rights Reserved.